Rezdiffra (Resmetirom) and Nicotine: Full Interaction Profile

What Is Resmetirom and How Does the Body Process It?

Resmetirom (brand name Rezdiffra) is a first-in-class, orally active, liver-directed thyroid hormone receptor beta agonist. The FDA granted approval on March 14, 2024, making it the first drug specifically approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (stages F2 and F3) in adults. The FDA approval letter and prescribing information are publicly accessible on the FDA website.

Understanding the interaction profile begins with understanding how the drug is cleared.

Primary Metabolic Pathway

Resmetirom is metabolized predominantly by CYP2C8, with a secondary contribution from CYP3A4. The FDA label identifies resmetirom as a CYP2C8 substrate and warns that strong CYP2C8 inhibitors (for example, gemfibrozil) can substantially increase resmetirom plasma exposure. The clinical pharmacology section of the resmetirom prescribing information details these pathways.

Transporter Involvement

Beyond cytochrome P450 enzymes, resmetirom is also a substrate of OATP1B1 and OATP1B3 hepatic uptake transporters. Inhibitors of these transporters, such as rifampin used as a single dose, increase resmetirom area under the curve (AUC). This transporter profile is relevant because some drugs that affect OATP activity (statins, cyclosporine) are commonly co-prescribed in MASH patients.

Protein Binding and Half-Life

Resmetirom is greater than 99% protein-bound and has a half-life of approximately 5 to 6 hours with once-daily dosing achieving steady-state concentrations rapidly. These pharmacokinetic characteristics shape how co-administered substances can alter drug exposure.

Does Nicotine Directly Interact With Resmetirom?

The short answer is no. No pharmacokinetic drug interaction between nicotine and resmetirom has been reported in the FDA label, the MAESTRO-NASH trial pharmacology data, or any peer-reviewed pharmacology publication as of mid-2025. This absence of interaction has a mechanistic basis worth understanding.

Nicotine's Metabolic Pathways

Nicotine is metabolized primarily by CYP2A6, which converts it to cotinine. CYP2B6 plays a smaller secondary role. A detailed review of nicotine metabolism published via the NIH confirms CYP2A6 as the dominant enzyme. Neither CYP2A6 nor CYP2B6 overlaps meaningfully with CYP2C8, the enzyme responsible for resmetirom clearance.

Why CYP2C8 Overlap Matters

CYP2C8 is not induced or inhibited by nicotine to a clinically significant degree. A 2001 phenotyping study published in the British Journal of Clinical Pharmacology established that smoking status does not alter CYP2C8 activity in a clinically meaningful way. That work is indexed through PubMed. Because resmetirom depends on CYP2C8 for its primary clearance, nicotine does not alter the drug's plasma levels.

What About Nicotine Replacement Products?

Nicotine replacement therapy (NRT) products, including the patch, gum, lozenge, and nasal spray, deliver nicotine without the combustion byproducts of tobacco smoke. From a pharmacokinetic standpoint, they carry the same negligible interaction risk as cigarette-derived nicotine with respect to resmetirom metabolism. However, the pharmacodynamic concerns discussed below still apply as long as nicotine itself is present in any form.

Pharmacodynamic Concerns: How Smoking Harms MASH Patients on Resmetirom

Even without a pharmacokinetic interaction, clinicians prescribing resmetirom should document and address tobacco and nicotine use. The concern is pharmacodynamic: nicotine and tobacco smoke worsen the disease that resmetirom is trying to treat.

Smoking and Hepatic Fibrosis Progression

Cigarette smoking is an independent risk factor for liver fibrosis in patients with metabolic liver disease. A cross-sectional analysis of NAFLD patients (N=575) published in the journal Alimentary Pharmacology and Therapeutics found that current smokers had a significantly higher odds of advanced fibrosis (F3/F4) compared with never-smokers after adjusting for BMI, diabetes, and alcohol use. That study is indexed on PubMed. Resmetirom's approval is specifically for F2 and F3 fibrosis; anything that accelerates fibrosis progression works directly against the drug's therapeutic goal.

Oxidative Stress and Hepatocyte Injury

Tobacco smoke generates reactive oxygen species that amplify hepatic oxidative stress. MASH pathophysiology involves mitochondrial dysfunction and lipid peroxidation, and smoking augments both mechanisms. A review of tobacco use and liver disease co-authored by Mayo Clinic hepatologists, available through PubMed, details these overlapping pathways.

Cardiovascular Risk Amplification

Most patients prescribed resmetirom have concomitant metabolic syndrome components, including dyslipidemia and insulin resistance. MASH patients already carry elevated atherosclerotic cardiovascular disease (ASCVD) risk. Smoking multiplies that baseline risk substantially. The American Heart Association estimates that smoking doubles the risk of coronary artery disease. AHA guidance on smoking and cardiovascular risk is available at americanheart.org. Since resmetirom was shown in MAESTRO-NASH to reduce LDL-C by roughly 13 to 15% at 52 weeks, smoking-driven cardiovascular risk can attenuate the net clinical benefit a patient receives.

Insulin Resistance and Metabolic Worsening

Nicotine itself, independent of other tobacco compounds, promotes insulin resistance through catecholamine release and adipokine dysregulation. A meta-analysis of 88 prospective studies published through NCBI confirms the association between tobacco use and type 2 diabetes risk. Since metabolic dysfunction drives MASH, any agent that worsens insulin resistance opposes the metabolic benefits resmetirom provides.

The MAESTRO-NASH Trial: What the Phase 3 Data Tell Us

The key registration trial for resmetirom is MAESTRO-NASH. Enrollment included 966 patients with biopsy-confirmed MASH and F2 or F3 fibrosis. The trial ran for 52 weeks and used histological endpoints: MASH resolution (defined as no steatohepatitis with no worsening of fibrosis) and fibrosis improvement of at least one stage with no worsening of MASH. The full NEJM publication of MAESTRO-NASH is available at nejm.org.

Primary Endpoint Results

At the 100 mg dose, 25.9% of resmetirom-treated patients achieved MASH resolution vs. 14.2% with placebo (P<0.001). Fibrosis improvement of at least one stage occurred in 29.9% vs. 19.9% with placebo (P<0.001). These numbers represent the benchmark against which any concomitant behavior, including smoking, should be evaluated for its potential to dilute benefit.

Lipid and Metabolic Outcomes

Resmetirom reduced LDL-C by 13.6%, non-HDL-C by 16.3%, and triglycerides by 22.7% at 52 weeks in the MAESTRO-NASH population. These lipid results are reported in the NEJM primary paper. Smoking attenuates lipid treatment effects through oxidative modification of LDL and reduced HDL function, meaning smokers on resmetirom may realize a smaller cardiovascular benefit than non-smokers.

Smoking Status at Baseline

The MAESTRO-NASH trial did not exclude smokers, and the published paper does not report a pre-specified subgroup analysis by smoking status. This absence of data means clinicians cannot point to a trial-proven efficacy reduction in smokers, only to the mechanistic rationale for concern. A post-hoc subgroup analysis by smoking status would be informative and has not been published as of mid-2025.

Alcohol and Resmetirom: The Co-Use Question

The secondary query about drinking on Rezdiffra warrants a dedicated section because alcohol is a far more direct hepatotoxic concern than nicotine for this patient population.

Alcohol as a Direct MASH Accelerant

MASH diagnosis requires the absence of significant alcohol consumption by definition (greater than 21 drinks per week in men or greater than 14 in women historically triggers reclassification). Even moderate alcohol use can worsen hepatic steatosis, inflammation, and fibrosis through multiple overlapping pathways, including mitochondrial toxicity, gut permeability changes, and acetaldehyde-mediated hepatocyte injury. A review in Hepatology Communications explores the overlap between alcoholic and metabolic liver disease, available via PubMed.

What the Resmetirom Label Says About Alcohol

The FDA-approved prescribing information for resmetirom does not list alcohol as a pharmacokinetic drug interaction. Alcohol does not inhibit CYP2C8 at physiologic blood alcohol concentrations in a clinically meaningful way. However, the label's clinical context section and the broader hepatology guidelines recommend that patients with MASH minimize or eliminate alcohol consumption entirely. The FDA label is accessible at accessdata.fda.gov.

Practical Guidance for Patients

Patients starting resmetirom should be counseled that alcohol consumption is not a direct pharmacokinetic interaction risk but does undermine the clinical rationale for the prescription. The Endocrine Society's 2023 clinical practice guidelines on metabolic liver disease recommend alcohol abstinence or near-abstinence in patients with MASH. Those guidelines are available through the Endocrine Society's journal platform.

Known Clinically Significant Drug Interactions With Resmetirom

This section provides context for how the nicotine non-interaction compares against substances that do interact with resmetirom. Prescribers should review the full label for all patients starting therapy.

Strong CYP2C8 Inhibitors

Gemfibrozil is the highest-concern inhibitor. Co-administration increases resmetirom AUC by approximately 2.3-fold. The FDA label states that concomitant use of strong CYP2C8 inhibitors should be avoided. The clinical pharmacology data are in the FDA label at accessdata.fda.gov.

OATP1B1/1B3 Inhibitors

Single-dose rifampin (an OATP inhibitor at single dose) increased resmetirom AUC by approximately 3.3-fold in drug interaction studies. Chronic rifampin (a CYP inducer) has the opposite effect, reducing exposure. Cyclosporine, another OATP inhibitor, is expected to increase resmetirom levels and should be used with caution.

Rosuvastatin and Statin Co-Administration

Resmetirom is also an inhibitor of OATP1B1, BCRP, and P-glycoprotein transport. It increases rosuvastatin AUC by approximately 2.2-fold. Patients who need statin therapy for ASCVD risk reduction, which describes most MASH patients given their cardiometabolic profile, should have statin doses adjusted according to the label's interaction table. Per the FDA label, pravastatin and lower doses of rosuvastatin are preferred.

Oral Contraceptives

Resmetirom inhibits BCRP and may increase ethinyl estradiol exposure. Women of childbearing potential who are not using highly effective contraception should not receive resmetirom given its teratogenic potential in animal studies.

Clinical Recommendations: Managing Nicotine Use in Resmetirom-Treated Patients

Addressing tobacco use in patients starting resmetirom is a clinical priority even without a direct pharmacokinetic interaction.

Cessation as an Adjunct to Pharmacotherapy

Varenicline (Chantix) is a first-line cessation pharmacotherapy with a strong evidence base. The EAGLES trial (N=8,144), published in The Lancet, demonstrated varenicline's superiority over bupropion, NRT, and placebo for 12-week continuous abstinence. The EAGLES trial publication is accessible via PubMed. Varenicline has no meaningful CYP2C8 interaction and does not appear to affect resmetirom pharmacokinetics based on available data.

NRT Safety Profile With Resmetirom

Nicotine patches, gum, and lozenges do not interact with resmetirom at the pharmacokinetic level. Prescribers can safely recommend NRT as a bridge to cessation without adjusting resmetirom dosing. The pharmacodynamic concern about nicotine worsening insulin resistance and oxidative stress remains, but the net benefit of eliminating combustion byproducts through NRT-assisted cessation outweighs the residual nicotine exposure.

Monitoring Liver Function in Smokers

The MAESTRO-NASH trial protocol included regular ALT and AST monitoring. Smokers on resmetirom should not require different biochemical monitoring intervals than non-smokers based on current evidence, but clinicians may choose to assess fibrosis trajectory more actively in patients who continue to smoke, given the independent fibrosis-promoting effect of tobacco. AASLD practice guidance on MASH management, including monitoring recommendations, is available at ncbi.nlm.nih.gov.

Documenting Tobacco and Nicotine Use Before Prescribing

Per USPSTF recommendations updated in 2021, every adult patient should be screened for tobacco use and offered cessation interventions. The USPSTF tobacco cessation recommendation is available at the USPSTF website. For resmetirom patients specifically, this screening takes on added relevance because continued smoking actively opposes the fibrosis-reducing goal of therapy.